Navigation Links
Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010

/i> and internationally, we could suffer penalties, or be required to pay substantial damages or make significant changes to our operations;
  • Government efforts to reduce healthcare costs and alter healthcare financing practices could lead to a decreased demand for our services or to reduced profitability;
  • Failure in continued execution of our Medicare Part D prescription drug program, and the integration of that program into a more comprehensive retiree strategy, could adversely impact our business and financial results;
  • PBMs could be subject to claims under ERISA if they are found to be a fiduciary of a health benefit plan governed by ERISA;
  • Pending litigation could adversely impact our business practices and have a material adverse effect on our business, financial condition, liquidity and operating results;
  • We are subject to corporate integrity agreements and noncompliance may impede our ability to conduct business with the federal government;
  • New legislative or regulatory initiatives that restrict or prohibit the PBM industry's ability to use patient identifiable medical information could limit our ability to use information that is critical to the operation of our business;
  • Our Specialty Pharmacy business is highly dependent on our relationships with a limited number of biopharmaceutical suppliers and the loss of any of these relationships could significantly impact our ability to sustain or improve our financial performance;
  • Our ability to grow our Specialty Pharmacy business could be limited if we do not expand our existing base of drugs or if we lose patients;
  • Our Specialty Pharmacy business, certain revenues from diabetes testing supplies and our Medicare Part D offerings expose us to increased credit risk;
  • Changes in indust

  • SOURCE Medco Health Solutions, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

    Related biology technology :

    1. Medco CEO to Shareholders: Delivering Results, Driving Shareholder Value
    2. Medco to Present at the Deutsche Bank 33rd Annual Health Care Conference
    3. Medco Issues $1.5 Billion of Senior Notes
    4. Addressing the Pharmacist Shortage: Medco Labor Coalition(TM) Launches National Scholarship Program to Support the Development of the Next Generation of Pharmacists
    5. Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the Worlds Largest, Most-Advanced Automated Pharmacy
    6. Medco to Webcast Annual Analyst Day Conference
    7. Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion
    8. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
    9. Fat droplet nanoparticle delivers tumor suppressor gene to tumor and metastatic cells
    10. Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion
    11. ICON Delivers New Electronic Solution to Expedite Clinical Trial Adjudication
    Post Your Comments:
    (Date:5/20/2015)... DIEGO , May 20, 2015  Cypher ... announced a collaboration with Celgene Corporation to apply ... genomic biomarkers that associate with patient response to ... is intended to help accelerate patient access to ... efficiencies in clinical research and development and potentially ...
    (Date:5/20/2015)... , May 19, 2015 Research and Markets ... addition of the "Bone Morphogenetic Proteins Market ... Trauma, Reconstructive and Oral - Maxillofacial) - Global ... 2014 - 2022" report to their offering. ... is studied based on the types of recombinant ...
    (Date:5/20/2015)... MA (PRWEB) May 20, 2015 ... transporter assay services for Drug-Drug Interactions (DDI), Metabolism ... Pharma, a world leader in assessing impact of ... Systems Pharmacology supported by biosimulation, announced today that ... agreement allows both companies to expand their product ...
    (Date:5/20/2015)... 20, 2015  HOSTING, the leading provider of ... is an official partner of the College ... Members Services Program. This unique collaboration leverages ... services and best practices derived from the ... service providers, enabling member healthcare organizations to ...
    Breaking Biology Technology:Cypher Genomics Collaborates with Celgene Corporation to Identify Novel Genomic Biomarkers 2Global Bone Morphogenetic Proteins Market Industry Analysis 2014 - 2022 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 3HOSTING Named Partner of the CHIME Cooperative Member Services Program 2HOSTING Named Partner of the CHIME Cooperative Member Services Program 3
    ... - Researchers are developing a new type of computer ... memory and use far less power than flash memory ... "ferroelectric" polymer, a material that switches polarity when electric ... ferroelectric transistor. "It,s in a very nascent stage," ...
    ... Renmatix , the leading producer of ... company,s commercial approach to producing sugars more cheaply ... industrial sugars, the foundation of the emerging bioindustrial ... fuels and chemicals to cost-effective biobased alternatives. ...
    ... Verenium Corporation (Nasdaq: VRNM ), a leading ... announced that it retired its remaining secured 9% Notes ... principal amount of unsecured 5.5% Notes outstanding. ... principal amount of its 9% Notes, the Company paid ...
    Cached Biology Technology:New 'FeTRAM' is promising computer memory technology 2Renmatix Reveals Supercritical Hydrolysis as Lowest-Cost Pathway to Cellulosic Sugar 2Renmatix Reveals Supercritical Hydrolysis as Lowest-Cost Pathway to Cellulosic Sugar 3Verenium Announces Debt Repurchase 2Verenium Announces Debt Repurchase 3
    (Date:5/11/2015)... May 11, 2015  Synaptics Incorporated (NASDAQ: ... solutions, today announced the appointment of Wajid ... Financial Officer, reporting to Rick Bergman , ... Chief Financial Officer, Kathleen Bayless , who ... Mr. Ali brings extensive financial management expertise ...
    (Date:5/11/2015)... Curemark LLC, a privately held drug research ... Phase III double blind, randomized, placebo-controlled clinical trial to ... all children ages 3-8 with Autism. Previously, Curemark announced ... blinded clinical trial for CM-AT in children ages 3-8 ... enzyme chymotrypsin. This new trial will help determine whether ...
    (Date:5/8/2015)... SAN JOSE, Calif. , May 8, 2015 ... human interface solutions, today announced that members of the executive ... J.P. Morgan 43rd Annual Technology, Media and Telecom Conference ... Westin Waterfront Hotel in Boston, MA ... Date: May 27, 2015 Time: 2:45pm ET Location: The New ...
    Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2
    ... better way to predict earthquakes and avalanches may soon ... at NJIT. Using mathematical modeling, researchers are ... "Computational Homology, Jamming and Force Chains ... Foundation grant has been awarded to Louis Kondic, associate ...
    ... taskswould have smiled at one of leptin,s mechanisms for curbing ... enlists the sympathetic nervous system to prevent bone-making cells from ... The study will appear online December 22, 2008 ( ... of The Journal of Cell Biology ( JCB ...
    ... Clive Svendsen,s lab dishes, he couldn,t have been more ... lost in patients with the devastating neurological disease spinal ... stem cell biologist had recreated the hallmarks of a ... from a patient. By allowing scientists the unparalleled ...
    Cached Biology News:To improve forecasting earthquakes, NJIT mathematician studies grains 2Leptin's long-distance call to the pancreas 2Patient-derived induced stem cells retain disease traits 2Patient-derived induced stem cells retain disease traits 3
    ... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Material: ...
    ... CLS number is a new product ... product number. If showing no availability ... Sigma-Aldrich number (Z71,517-4) or contact customer ... polystyrene (expanded surface, easy grip) ...
    Formula variant: With macro- and micronutrients. Physical Form: powder Suitab tst: plant cell culture tested...
    BD Falcon 850 cm Smooth-surface TufRol Roller Bottle, tissue-culture treated polystyrene, blow-molded one-piece design, with easy on/off non-vented cap. (2/sp, 20/ca) Packaging: 2 / pack, 20 /...
    Biology Products: